Home Study Webcast
1 Contact Hour(s)
Thursday, October 31, 2019
Saturday, April 30, 2022
ACPE Expiration Date
Monday, October 31, 2022
As more states legalize cannabis for medicinal use as well as for adult non-medical use, 33 states and 10 states respectively, it is incumbent upon clinicians practicing in oncology to have a confident, evidence-based ability to discuss the potential risks and benefits with their patients. Much of the controversy surrounding medical cannabis is currently the relative availability and interest with a corresponding lack of evidence to help clinicians understand what its role may be. Since 1970 with the passage of the controlled substances act very little high quality, consistent, medical research was able to be performed on marijuana and its various components. Now with the current regulatory environment changing in regard to marijuana, there are many claims being made in regard to the beneficial effect and minimizing the potential harms of marijuana.
What we do know is that there may be some benefits for cancer patients to use marijuana in a controlled manner, for symptoms that include pain, nausea, appetite stimulation and sleep. The issue that many clinicians who practice in oncology face is that while there may be some benefit to the adjunctive use of cannabis, there is a panacea of available preparations and a wide variety of dosages- all with different proportions of the more than 60 potentially pharmaceutically active phytocannabinoids. These preparations may include capsules, gummies, chocolates, edibles, tinctures, oils and flowers. Each preparation has slightly different release characteristics, which is likely to affect the final therapeutic effect. In order to safely and effectively counsel our patients we must familiarize ourselves with both the evidence-based medicine and the real world logistical issues of dose finding and titration. This talk will provide a sound basis for clinicians to begin to more comfortably speak with their patients about medical cannabis.
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.
In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.
Clinical Pharmacy Specialist, Palliative Care; Dana Farber Cancer Institute
This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).